Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations

Katarina Mitrova; Mette Julsgaard; Patrick Augustijns; Karin Cerna; Uma Mahadevan; Dana Duricova; Pregnancy study group

doi:10.1016/j.cgh.2024.01.019

Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations

Katarina Mitrova^*, Mette Julsgaard, Patrick Augustijns, Karin Cerna, Uma Mahadevan, Dana Duricova, Pregnancy study group

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Letter › peer review

Abstract

Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC). 1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation. 2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib. 4-7.

Originalsprog	Engelsk
Tidsskrift	Clinical Gastroenterology and Hepatology
ISSN	1542-3565
DOI	https://doi.org/10.1016/j.cgh.2024.01.019
Status	E-pub ahead of print - 1 feb. 2024

Bibliografisk note

Adgang til dokumentet

10.1016/j.cgh.2024.01.019

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{759926168dd6488ebbd661ed5e4d596d,

title = "Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations",

abstract = "Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC). 1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation. 2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib. 4-7. ",

author = "Katarina Mitrova and Mette Julsgaard and Patrick Augustijns and Karin Cerna and Uma Mahadevan and Dana Duricova and {Pregnancy study group}",

year = "2024",

month = feb,

day = "1",

doi = "10.1016/j.cgh.2024.01.019",

language = "English",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B.Saunders Co.",

}

TY - JOUR

T1 - Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations

AU - Mitrova, Katarina

AU - Julsgaard, Mette

AU - Augustijns, Patrick

AU - Cerna, Karin

AU - Mahadevan, Uma

AU - Duricova, Dana

AU - Pregnancy study group

PY - 2024/2/1

Y1 - 2024/2/1

N2 - Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC). 1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation. 2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib. 4-7.

AB - Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC). 1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation. 2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib. 4-7.

UR - http://www.scopus.com/inward/record.url?scp=85187990444&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2024.01.019

DO - 10.1016/j.cgh.2024.01.019

M3 - Letter

C2 - 38309493

SN - 1542-3565

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

ER -

Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations

Abstract

Bibliografisk note

Adgang til dokumentet

AUB Link

Andre filer og links

Fingeraftryk

Citationsformater